In summary, our findings provide insight into the anti-T-ALL leukemic effect of NF-κB and JNK combined-inhibitor treatment and support further evaluation of these molecules as promising agents for novel therapeutic interventions with other chemotherapeutic agents for the treatment of such fatal diseases as T-ALL. This evidence concerns the gene MAPK8 and acute lymphoblastic leukemia.